These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High density lipoprotein (HDL) particle composition in patients with end stage renal failure (ESRF) on chronic dialysis. Lee P; O'Neal D; Murphy B; Best J Aust N Z J Med; 1997 Jun; 27(3):285-93. PubMed ID: 9227812 [TBL] [Abstract][Full Text] [Related]
3. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Deighan CJ; Caslake MJ; McConnell M; Boulton-Jones JM; Packard CJ Am J Kidney Dis; 2000 May; 35(5):852-62. PubMed ID: 10793019 [TBL] [Abstract][Full Text] [Related]
4. Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients. Kimak E; Hałabiś M; Baranowicz-Gąszczyk I; Solski J; Książek A J Zhejiang Univ Sci B; 2011 May; 12(5):365-71. PubMed ID: 21528490 [TBL] [Abstract][Full Text] [Related]
5. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease. Tsumura M; Kinouchi T; Ono S; Nakajima T; Komoda T Clin Chim Acta; 2001 Dec; 314(1-2):27-37. PubMed ID: 11718676 [TBL] [Abstract][Full Text] [Related]
6. Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients. Hörkkö S; Huttunen K; Läärä E; Kervinen K; Kesäniemi YA Ann Med; 1994 Aug; 26(4):271-82. PubMed ID: 7946245 [TBL] [Abstract][Full Text] [Related]
7. Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Sniderman A; Cianflone K; Kwiterovich PO; Hutchinson T; Barre P; Prichard S Atherosclerosis; 1987 Jun; 65(3):257-64. PubMed ID: 3619989 [TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020 [TBL] [Abstract][Full Text] [Related]
9. LDL and HDL subclass distribution in patients with end-stage renal diseases. Alabakovska SB; Todorova BB; Labudovic DD; Tosheska KN Clin Biochem; 2002 May; 35(3):211-6. PubMed ID: 12074829 [TBL] [Abstract][Full Text] [Related]
10. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225 [TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. O'Neal D; Lee P; Murphy B; Best J Am J Kidney Dis; 1996 Jan; 27(1):84-91. PubMed ID: 8546142 [TBL] [Abstract][Full Text] [Related]
13. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B Nephron; 1996; 72(2):135-44. PubMed ID: 8684516 [TBL] [Abstract][Full Text] [Related]
14. Cell cholesterol transport to plasma in blood from patients with renal failure or a kidney transplant. Sutherland WH; Corboy J; Walker RJ; Robertson MC; Ball MJ Nephrol Dial Transplant; 1995; 10(3):358-65. PubMed ID: 7792031 [TBL] [Abstract][Full Text] [Related]
15. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins. Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239 [TBL] [Abstract][Full Text] [Related]
16. Effect of beta-blocker therapy on serum lipoprotein profiles in patients on renal dialysis and in diabetic nephropathy. Kontessis PS; Jayathissa SA; Walker JD; Mattock MB; Williams DG; Viberti GC Diabetes Res; 1993; 23(3):93-104. PubMed ID: 7712687 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Saltissi D; Westhuyzen J; Morgan C; Healy H Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078 [TBL] [Abstract][Full Text] [Related]
18. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients. González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671 [TBL] [Abstract][Full Text] [Related]
19. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Gluba-Brzózka A; Franczyk B; Banach M; Rysz-Górzyńska M Int Urol Nephrol; 2017 Jan; 49(1):155-164. PubMed ID: 27942970 [TBL] [Abstract][Full Text] [Related]
20. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Nauck M; Krämer-Guth A; Bartens W; März W; Wieland H; Wanner C Clin Nephrol; 1996 Nov; 46(5):319-25. PubMed ID: 8953121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]